A synthetic peptide from AA 120-170 of human DCTN1 conjugated to an immunogenic carrier protein was used as the antigen. The peptide is homologous in rat and moue.
DCTN1
Reaktivität: Human
WB, ELISA
Wirt: Maus
Monoclonal
2E4-1C2
unconjugated
Applikationshinweise
IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.
Handhabung
Avoid freeze and thaw cycles.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
FUNCTION: Required for the cytoplasmic dynein-driven retrograde movement of vesicles and organelles along microtubules. Dynein-dynactin interaction is a key component of the mechanism of axonal transport of vesicles and organelles. SUBUNIT: Large macromolecular complex of at least 10 components, p150(glued) binds directly to microtubules and to cytoplasmic dynein. Interacts with the C-terminus of MAPRE1, MAPRE2 and MAPRE3. SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton. TISSUE SPECIFICITY: Brain. DISEASE: Defects in DCTN1 are the cause of progressive lower motor neuron disease. PLMND is a progressive dominant disease that has no sensory symptoms.,Signal Transduction,DAP-150, DP-150, p150-glued,p135, Dynactin subunit 1, 150 kDa dynein-associated polypeptide